Display search results for ** instead (81 products)

Showing 1-10 of 81

12 Feb 2016  |  Global

Vital Signs - Impact of Strategic Acquisitions on Life Sciences Market, 2016

Portfolio Expansions Follow Acquisitions by Panasonic Healthcare Holdings Co.,Thermo Fisher Scientific and Abbott Laboratories

This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.

USD 450.00

USD 337.50 save 25 %

04 Feb 2016  |  Global

Vital Signs - Spiraling US Drug Costs, Wearable Healthcare Technologies and the Zika Virus, An Analysis

Urgent Remedial Action Required as Nearly 1/4th US Prescription Drug Users Find it Difficult to Afford their Prescriptions

This issue of Vital Signs discusses why the US pays more than other countries for drugs, the inside story on wearable electronics, the spreading Zika virus, and soaring US drug costs.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

USD 450.00

USD 337.50 save 25 %

This edition of the Genetic Technology TOE depicts life sciences trends across the biopharmaceutical industry. Different genetic technologies, antibody drug conjugates, mitochondrial based therapies are illustrated. The corresponding clinical trials scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Oppo...

USD 250.00

USD 187.50 save 25 %

This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included. The Genetic Technology TechVision Opportunity Engine (TOE) p...

USD 250.00

USD 187.50 save 25 %

This edition of the Genetic Technology TOE depicts trends across technologies that enable dendritic cell targeting for autoimmune/inflammatory disease therapy. Respiratory inflammation, myasthenia gravis, systemic lupus erytematosus, and other autoimmune disorders are profiled in the TOE. Recent patents related to dendritic cell targeting for autoi...

USD 250.00

USD 187.50 save 25 %

01 Dec 2017  |  Global

Technologies Enabling Improved Skincare

This edition of the Genetic Technology TOE depicts life sciences trends across skincare. Recombinant DNA technology, probiotic formulations, and phage proteins for enhanced skincare are profile in the TOE. The corresponding technology innovation scenario across skin microbiome and ageing is depicted. The Genetic Technology TechVision Opportunity E...

USD 250.00

USD 187.50 save 25 %

This edition of the Genetic Technology TOE depicts the life sciences trends across recent genetic technology and biopharma advances. Genetic technology, biopharmaceuticals development and regulatory approval, CRISPR/Cas9 gene editing technology, and CAR-T cell therapy are profiled in the TOE. The corresponding clinical trials scenario for genetical...

USD 250.00

USD 187.50 save 25 %

Showing 1-10 of 81